Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the ur...
Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium
About this item
Full title
Author / Creator
Publisher
England: Elsevier Limited
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Limited
Subjects
More information
Scope and Contents
Contents
Summary Front-line platinum-based combination chemotherapy leads to high response rates but suboptimum overall survival for patients with advanced transitional-cell carcinoma of the urothelium. Bevacizumab is being assessed in combination with platinum-based first-line chemotherapy in a large phase 3 trial. Current second-line systemic therapies, i...
Alternative Titles
Full title
Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_754015856
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_754015856
Other Identifiers
ISSN
1470-2045
E-ISSN
1474-5488
DOI
10.1016/S1470-2045(10)70086-3
